Viking Therapeutics: A Dance of Science and Speculation

And yet, dear reader, let us not mistake panic for truth. For beneath this tempest lies a curious signal: at just 13 weeks, VK2735 achieved a weight loss of 12.2%. Compare this, though imperfectly, to Eli Lilly‘s orforglipron and Novo Nordisk‘s oral semaglutide, whose respective triumphs of 12.4% and 15% were measured over 68 to 72 weeks. Yes, tolerability concerns loomed large-the discontinuation rate was 28%, compared to placebo’s 18%, driven chiefly by gastrointestinal woes-but is this not merely a matter of refinement? Surely, dosing protocols can be tempered, as one might calm a skittish horse.







